The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 3, 2001, Pages 497-529

  Grimwade, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute promyelocytic leukaemia; AML; Chromosomal translocation; Clinical trials; Cryptic and variant translocations; Cytogenetics; FISH; Minimal residual disease; RT PCR

Indexed keywords

CORE BINDING FACTOR; TRANSCRIPTION FACTOR ETS 1; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOGENETICS; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE INSERTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFANT; KARYOTYPING; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MOLECULAR DYNAMICS; MORPHOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034758836     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0152     Document Type: Article

References (172)

1. Chromosomal translocations in human cancer
2. Oncogenic transcription factors in the human acute leukemias
3. The EVII gene in myeloid leukemia
4. Molecular evaluation of acute myeloid leukemias
5. Leukemogenesis by CBF oncoproteins
6. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
7. The role of homeobox genes in normal hematopoiesis and hematological malignancies
8. Chromatin remodeling and leukemia: New therapeutic paradigms
9. The role of chromosome translocations in leukemogenesis
10. The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB-binding protein
11. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia
12. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22)
13. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3)
14. Adenoviral EIA-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13)
15. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9
16. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosomal translocation t(7;11)(p15;p15) in human myeloid leukemia
17. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia
18. An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation
19. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of a chimaeric, leukemia-specific dek-can mRNA
20. A novel gene NSDI, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia
21. Leukemia and the disruption of normal hematopoiesis
22. The pathogenesis of acute promyelocytic leukaemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease
23. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
24. A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia
25. Two critical hits for promyelocytic leukemia
26. Analysis of the role of AMLI-ETO in leukemogenesis, using an inducible transgenic mouse model
27. Expression of AMLI-ETO immortalizes myeloid progenitors and cooperates with secondary mutations to induce granulocytic sarcoma/acute myeloid leukemia
28. The PEBP2betaMYHII fusion created by inv(16)(p13q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia
29. The fusion gene Cbfβ-MYHII blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia
30. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
31. RT-PCR method with increased sensitivity shows persistence of PML-RARα fusion transcripts in patients in long-term remission of APL
32. AMLI/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
33. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation
34. Prenatal origin of acute lymphoblastic leukaemia in children
35. TEL-AMLI and AMLI-ETO fusion sequences in normal newborn cord bloods
36. Partial duplication of HRX in acute leukemia with trisomy 11
37. Partial tandem duplication of ALLI as a recurrent molecular defect in acute myeloid leukemia with trisomy 11
38. High incidence of biallelic point mutations in the Runt domain of the AMLI/PEBP2αB gene in MO acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21
39. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
40. Leukaemia diagnosis. A guide to the FAB classification
41. Clinical significance of cytogenetics of acute myeloid leukemia
42. A new morphological classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF-RARα rearrangements
43. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia
44. 8;21 translocation in acute granulocytic leukaemia: Cytological, cytochemical and clinical features
45. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: A clinical review
46. Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL
47. The translocation t(8;16)(p11;p13) defines an AML subtype with distinct cytology and clinical features
48. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): Results of the European Working Party
49. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid
50. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
51. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia
52. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
53. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
54. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors
55. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations
56. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region
57. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis
58. The Partial tandem duplication of ALLI (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia
59. Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered
60. Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non-specific recombination between the PML and RARA genes within identical short stretches
61. Microclustering of TEL-AMLI translocation breakpoints in childhood acute lymphoblastic leukemia
62. Hypothesis: Phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia
63. Revised classification of acute myeloid leukemia
64. Low NAD(P)H:quinone oxidoreductase I activity is associated with increased risk of acute leukemia in adults
65. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia
66. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia
67. The AMLI-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance
68. Characterisation of the PML/RARα rearrangement associated with t(15;17) acute promyelocytic leukaemia
69. Cell death induction by the promyelocytic leukemia-specific PML/RAR alpha fusion protein
70. The nuclear topography of ABL, BCR, PML, and RARα genes: Evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation
71. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
72. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy
73. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study - POG 8821
74. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
75. Hunting 11q23 deletions with fluorescence in situ hybridization (FISH)
76. Large deletions 5′ to the ETO breakpoint are observed in 10% of patients with t(8;21)-positive AML
77. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
78. Detection of the AMLI/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia
79. Correlation between cell morphology and expression of the AMLI/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21)
80. Molecular detection of t(8;21)/AMLI-ETO in AML MI/M2: Correlation with cytogenetics, morphology and immunophenotype
81. Simple variant t(8;21) acute myeloid leukemias harbor insertions of the AMLI or ETO genes
82. FISH identifies inv(16)(p13q22) masked by translocations in three cases of acute myeloid leukemia
83. CBFB/MYHII fusion in a patient with AML-M4Eo and cytogenetically normal chromosomes 16
84. Detection of karyotypic aberrations in acute myeloblastic leukaemia: A prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML
85. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia
86. Fourth International Workshop on Chromosomes in Leukemia in 1982: Clinical significance of chromosomal abnormalities in acute non-lymphoblastic leukemia
87. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients
88. The clinical significance of karyotype in acute myelogenous leukemia
89. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia - Analysis of 848 patients
90. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) analysis of 1065 patients entered into the United Kingdom Medical Research Council AML II trial
91. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
92. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases
93. Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia
94. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study
95. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: Results from Cancer and Leukemia Group B 8461
96. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): Both rearrangements are associated with a poor prognosis
97. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
98. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial
99. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
100. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses
101. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia
102. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
103. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
104. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: Impact of cytogenetics on achieving a complete remission
105. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: A study of 90 patients
106. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
107. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House. Virginia, November 1997
108. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study
109. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
110. Transplantation in first remission of acute myeloid leukemia
111. Hierarchical cytogenetic classification is highly predictive of outcome in AML arising at all ages: Analysis of 4225 cases entered in the UK MRC leukaemia trials
112. Incidence of AMLI/ETO fusion transcripts in patients entered into the MRC AML trials
113. Frequency of CBFβ/MYHII fusion transcripts in patients entered into the UK MRC AML trials
114. Identification of the t(15;17) in FAB types other than M3: Evaluation of the role of molecular screening for the PML-RARα rearrangement in newly diagnosed AML
115. 3)in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
116. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
117. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial
118. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
119. Therapy of molecular relapse in acute promyelocytic leukemia
120. Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: A comparison with cytogenetics and RT-PCR in MRC ATRA trial patients
121. Rearrangement of ALLI (MLL) in acute myeloid leukemia with normal cytogenetics
122. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML
123. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
124. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia
125. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial
126. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
127. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α in acute myeloid leukemia
128. Prognostic implication of Flt3 and N-Ras gene mutations in acute myeloid leukemia
129. EVII expression in acute myeloid leukaemia
130. Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia
131. IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: Application to the analysis of seven human prostate cell lines
132. A new recurrent translocation. t(5;11)(q35;p15.5) associated with del(5q) in childhood acute myeloid leukemia
133. Secondary chromosomal abnormalities in acute leukemias
134. Recurring chromosomal abnormalities in leukemia in PML-RARα transgenic mice parallel human acute promyelocytic leukemia
135. Acquired, non-random chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice
136. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF
137. Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth
138. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice
139. Frequency and clinical significance of the expression of the multidrug resistance proteins MDRI/P-glycoprotein, MRPI, and LRP in acute myeloid leukemia
140. Simultaneous activity of MRPI and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult myeloid leukemia
141. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
142. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia
143. The amount of spontaneous apoptosis predicts outcome in acute myeloid leukemia (AML)
144. The immunophenotype of 177 adults with acute myeloid leukemia: Proposal of a prognostic score
145. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia
146. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
147. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
148. Expression profiling reveals fundamental biologic differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics
149. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
150. MLL rearrangements in haematological malignancies: Lessons from clinical and biological studies
151. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia
152. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11)(p21;q23)
153. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q
154. AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14)
155. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors
156. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: Evidence for its fusion with MLL in acute myeloid leukemia
157. A novel gene, MELI, mapped to 1p36.3 is highly homologous to the MDSI/EVII gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells
158. NUP98 is fused to PMXI homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15)
159. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF)
160. Fusion of the MORF and CBP genes in acute myeloid leukemia with t(10;16)(q22;p13)
161. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion
162. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): Molecular cloning of both reciprocal transcripts
163. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12)
164. Signal transduction and transforming properties of the TEL-TRKC fusions associated with congenital fibrosarcoma and acute myelogenous leukemia
165. t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (GUANOSINE 5′ MONOPHOSPHATE SYNTHETASE) gene
166. Human LPP gene is fused to MLL in a secondary acute leukemia with a t(3;11)(q28;q23)
167. The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogenous leukemia
168. t(11;14)(q23;q24) generates an MLL-human gephyrin fusion gene along with a de facto truncated MLL in acute monoblastic leukemia
169. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia
170. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)
171. An ins(X;11)(q24;q23) fuses the MLL and the Septin 6/KIAA01 gene in an infant with AML-M2
172. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13)